

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/278585 A1

(43) International Publication Date
05 January 2023 (05.01.2023)

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
C07K 16/30 (2006.01) A61P 35/00 (2006.01)

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2022/035533

(22) International Filing Date:

29 June 2022 (29.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/216,616 30 June 2021 (30.06.2021) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US).

(72) Inventors: **QI, Wei**; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US). **REN, Cindy**; c/o Amgen Inc., One Amgen Center Drive, Mail Stop 28-5-A, Thousand Oaks, CA 91320-1799 (US).

(74) Agent: **KISSLING, Heather, R.** et al.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHOD OF RECONSTITUTING LYOPHILIZED FORMULATION

(57) Abstract: Described herein is a method comprising (a) reconstituting a lyophilized formulation comprising a polypeptide, a saccharide, a surfactant, and a buffer, with a diluent comprising an aromatic alcohol, a phenolic compound, or an amino acid with aromatic side chain, and (b) administering the reconstituted formulation to a subject in need thereof within 12 hours of reconstitution, wherein the polypeptide is a bispecific antibody construct, such as a bispecific antibody construct that binds human DLL3 and human CD3 and optionally comprises the amino acid sequence of SEQ ID NO: 75 and SEQ ID NO: 9.

WO 2023/278585 A1